Dremisan Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dremisan

msf marketing service gmbh - simeticon - granulat - simeticon 3.g

Pegasys 135 mcg/0,5 ml Injektionslösung in einer Fertigspritze Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pegasys 135 mcg/0,5 ml injektionslösung in einer fertigspritze

cps cito pharma services gmbh - peginterferonum alfa-2a - injektionslösung in einer fertigspritze - peginterferonum alfa-2a 135 µg, natrii chloridum, alcohol benzylicus 5 mg, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, natrii acetas trihydricus aut acidum aceticum ad ph, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.8 mg. - chronische hepatitis b, chronische hepatitis c - biotechnologika

Pegasys 180 mcg/0,5 ml Injektionslösung in einer Fertigspritze Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pegasys 180 mcg/0,5 ml injektionslösung in einer fertigspritze

cps cito pharma services gmbh - peginterferonum alfa-2a - injektionslösung in einer fertigspritze - peginterferonum alfa-2a 180 µg, natrii chloridum, alcohol benzylicus 5 mg, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, natrii acetas trihydricus aut acidum aceticum ad ph, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.8 mg. - chronische hepatitis b, chronische hepatitis c - biotechnologika

Irinotecan onkovis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

irinotecan onkovis 20 mg/ml konzentrat zur herstellung einer infusionslösung

onkovis gmbh (8111905) - irinotecanhydrochlorid 3 h<2>o - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; irinotecanhydrochlorid 3 h<2>o (28859) 20 milligramm

Celdoxome pegylated liposomal Europäische Union - Deutsch - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doxorubicinhydrochlorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastische mittel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).